Your browser doesn't support javascript.
loading
Toward best practice in cancer mutation detection with whole-genome and whole-exome sequencing.
Xiao, Wenming; Ren, Luyao; Chen, Zhong; Fang, Li Tai; Zhao, Yongmei; Lack, Justin; Guan, Meijian; Zhu, Bin; Jaeger, Erich; Kerrigan, Liz; Blomquist, Thomas M; Hung, Tiffany; Sultan, Marc; Idler, Kenneth; Lu, Charles; Scherer, Andreas; Kusko, Rebecca; Moos, Malcolm; Xiao, Chunlin; Sherry, Stephen T; Abaan, Ogan D; Chen, Wanqiu; Chen, Xin; Nordlund, Jessica; Liljedahl, Ulrika; Maestro, Roberta; Polano, Maurizio; Drabek, Jiri; Vojta, Petr; Kõks, Sulev; Reimann, Ene; Madala, Bindu Swapna; Mercer, Timothy; Miller, Chris; Jacob, Howard; Truong, Tiffany; Moshrefi, Ali; Natarajan, Aparna; Granat, Ana; Schroth, Gary P; Kalamegham, Rasika; Peters, Eric; Petitjean, Virginie; Walton, Ashley; Shen, Tsai-Wei; Talsania, Keyur; Vera, Cristobal Juan; Langenbach, Kurt; de Mars, Maryellen; Hipp, Jennifer A.
Afiliación
  • Xiao W; The Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD, USA. wenming.xiao@fda.hhs.gov.
  • Ren L; State Key Laboratory of Genetic Engineering, Human Phenome Institute, School of Life Sciences and Shanghai Cancer Center, Fudan University, Shanghai, China.
  • Chen Z; Center for Genomics, Loma Linda University School of Medicine, Loma Linda, CA, USA.
  • Fang LT; Bioinformatics Research & Early Development, Roche Sequencing Solutions Inc., Belmont, CA, USA.
  • Zhao Y; Advanced Biomedical and Computational Sciences, Biomedical Informatics and Data Science Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Lack J; Advanced Biomedical and Computational Sciences, Biomedical Informatics and Data Science Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Guan M; SAS Institute Inc., Cary, NC, USA.
  • Zhu B; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
  • Jaeger E; Illumina Inc., Foster City, CA, USA.
  • Kerrigan L; ATCC, Manassas, VA, USA.
  • Blomquist TM; Departments of Medicine and Pathology, University of Toledo Medical Center, Toledo, OH, USA.
  • Hung T; Genentech, South San Francisco, CA, USA.
  • Sultan M; Biomarker Development, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Idler K; Computational Genomics, Genomics Research Center, AbbVie, North Chicago, IL, USA.
  • Lu C; Computational Genomics, Genomics Research Center, AbbVie, North Chicago, IL, USA.
  • Scherer A; Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland.
  • Kusko R; European Infrastructure for Translational Medicine, Amsterdam, the Netherlands.
  • Moos M; Immuneering Corporation, Cambridge, MA, USA.
  • Xiao C; The Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
  • Sherry ST; National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD, USA.
  • Abaan OD; National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD, USA.
  • Chen W; Illumina Inc., Foster City, CA, USA.
  • Chen X; Seven Bridges Genomics Inc., Cambridge, MA, USA.
  • Nordlund J; Center for Genomics, Loma Linda University School of Medicine, Loma Linda, CA, USA.
  • Liljedahl U; Center for Genomics, Loma Linda University School of Medicine, Loma Linda, CA, USA.
  • Maestro R; European Infrastructure for Translational Medicine, Amsterdam, the Netherlands.
  • Polano M; Department of Medical Sciences, Molecular Medicine and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
  • Drabek J; European Infrastructure for Translational Medicine, Amsterdam, the Netherlands.
  • Vojta P; Centro di Riferimento Oncologico di Aviano IRCCS, National Cancer Institute, Unit of Oncogenetics and Functional Oncogenomics, Aviano, Italy.
  • Kõks S; European Infrastructure for Translational Medicine, Amsterdam, the Netherlands.
  • Reimann E; Centro di Riferimento Oncologico di Aviano IRCCS, National Cancer Institute, Unit of Oncogenetics and Functional Oncogenomics, Aviano, Italy.
  • Madala BS; European Infrastructure for Translational Medicine, Amsterdam, the Netherlands.
  • Mercer T; Centro di Riferimento Oncologico di Aviano IRCCS, National Cancer Institute, Unit of Oncogenetics and Functional Oncogenomics, Aviano, Italy.
  • Miller C; European Infrastructure for Translational Medicine, Amsterdam, the Netherlands.
  • Jacob H; IMTM, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic.
  • Truong T; European Infrastructure for Translational Medicine, Amsterdam, the Netherlands.
  • Moshrefi A; IMTM, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic.
  • Natarajan A; European Infrastructure for Translational Medicine, Amsterdam, the Netherlands.
  • Granat A; Perron Institute for Neurological and Translational Science, Nedlands, Perth, Western Australia, Australia.
  • Schroth GP; Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Murdoch, Perth, Western Australia, Australia.
  • Kalamegham R; European Infrastructure for Translational Medicine, Amsterdam, the Netherlands.
  • Peters E; Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia.
  • Petitjean V; Garvan Institute of Medical Research, The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia.
  • Walton A; Garvan Institute of Medical Research, The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia.
  • Shen TW; Computational Genomics, Genomics Research Center, AbbVie, North Chicago, IL, USA.
  • Talsania K; Computational Genomics, Genomics Research Center, AbbVie, North Chicago, IL, USA.
  • Vera CJ; Illumina Inc., Foster City, CA, USA.
  • Langenbach K; Illumina Inc., Foster City, CA, USA.
  • de Mars M; Illumina Inc., Foster City, CA, USA.
  • Hipp JA; Illumina Inc., Foster City, CA, USA.
Nat Biotechnol ; 39(9): 1141-1150, 2021 09.
Article en En | MEDLINE | ID: mdl-34504346
ABSTRACT
Clinical applications of precision oncology require accurate tests that can distinguish true cancer-specific mutations from errors introduced at each step of next-generation sequencing (NGS). To date, no bulk sequencing study has addressed the effects of cross-site reproducibility, nor the biological, technical and computational factors that influence variant identification. Here we report a systematic interrogation of somatic mutations in paired tumor-normal cell lines to identify factors affecting detection reproducibility and accuracy at six different centers. Using whole-genome sequencing (WGS) and whole-exome sequencing (WES), we evaluated the reproducibility of different sample types with varying input amount and tumor purity, and multiple library construction protocols, followed by processing with nine bioinformatics pipelines. We found that read coverage and callers affected both WGS and WES reproducibility, but WES performance was influenced by insert fragment size, genomic copy content and the global imbalance score (GIV; G > T/C > A). Finally, taking into account library preparation protocol, tumor content, read coverage and bioinformatics processes concomitantly, we recommend actionable practices to improve the reproducibility and accuracy of NGS experiments for cancer mutation detection.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Análisis de Secuencia de ADN / Benchmarking / Secuenciación Completa del Genoma / Secuenciación del Exoma / Neoplasias Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies Límite: Humans Idioma: En Revista: Nat Biotechnol Asunto de la revista: BIOTECNOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Análisis de Secuencia de ADN / Benchmarking / Secuenciación Completa del Genoma / Secuenciación del Exoma / Neoplasias Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies Límite: Humans Idioma: En Revista: Nat Biotechnol Asunto de la revista: BIOTECNOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos